News & Events about Maxcyte Inc.
Globe Newswire
6 months ago
MaxCytes Scientific Advisory Board will provide guidance to shape the technical direction of the companys innovation initiatives focused on the discovery, development and manufacturing of next-generation, cell-based medicinesROCKVILLE, Md., March 08, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: ...
Globe Newswire
10 months ago
Curamys to use MaxCytes Flow Electroporation technology and ExPERT platform to help advance its cell fusion technology.ROCKVILLE, Md. and SEOUL, South Korea, Dec. 04, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling ...
Ticker Report
11 months ago
MaxCyte, Inc. (NASDAQ:MXCT Get Rating) EVP Thomas M. Ross sold 4,282 shares of the businesss stock in a transaction that occurred on Tuesday, October 11th. The stock was sold at an average price of $6.51, for a total transaction of $27,875.82. The transaction was disclosed in a filing...
MaxCyte (NASDAQ:MXCT Get Rating) had its target price raised by BTIG Research from $10.00 to $11.00 in a report issued on Sunday, The Fly reports. MaxCyte Price Performance Shares of MXCT opened at $5.87 on Friday. The stock has a market capitalization of $596.55 million and a P/E ratio of -...
GAITHERSBURG, Md., July 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, ...